Skip to main content
. Author manuscript; available in PMC: 2016 May 5.
Published in final edited form as: Vaccine. 2015 Mar 25;33(19):2261–2266. doi: 10.1016/j.vaccine.2015.03.029

Figure 1. Schematic showing mouse groups and sampling regimen in ma-EBOV challenge study of MCMV/ZEBOV-NPCTL.

Figure 1

C57BL/6 (H2b-restricted) mice were immunized using a single IP dose of 5×105 pfu of MCMV/ZEBOV-NPCTL. Control groups received MCMV WT or diluent (Mock). Splenocytes were harvested for analysis of T cell responses in groups of mice at times indicated (week 8/9: days 56, 58, 65 post-vaccination, and prior to challenge: days 96 and 100 post-vaccination). Antigen specific T cells were assayed by using ICS with a 6 hour incubation in the presence of BFA with peptide. After 119 days (approx. 4 months) post-vaccination, mice were challenged with 1×103 LD50 ma-EBOV IP and disease course was followed for 28 days. VZVΔG/ZEBOVGP vaccinated mice served as a vaccine efficacy control group, and received a single IP dose of VZVΔG/ZEBOVGP (5×105 pfu) prior to the ma-EBOV challenge (47 days later).